News · Halozyme Therapeutics, Inc. (HALO) · Healthcare

Halozyme rises 0.5% as insider sales and earnings date loom

Session of October 9, 2026 · Published October 12, 2026 · 4 min read

What happened

Halozyme (HALO) rose 0.5% on October 9, 2026, in an ordinary session as the company disclosed executive share sales and headed into its next earnings report. The stock closed at $110.42, giving the company a market value of $13.10 billion. Trading volume was 0.7 times its 20-day average as the S&P 500 rose 0.6% and the healthcare sector median rose 1.4% on the day.

Closing price over the last 30 trading sessions. On October 9, 2026, HALO closed at $110.42, up 0.5% on the day and 4.8% higher than 30 sessions earlier.

How big was the move

The session was small relative to the stock’s own volatility: the move measured 0.2 times a typical daily move for this stock, an ordinary session by that metric. Over the last five sessions the stock rose 0.5%, matching the one-day change and signalling little short-term dislocation. The stock’s market sensitivity was low, with a beta of 0.31, meaning the stock tends to move less than the market. This session’s price action was 0.8 percentage points worse than the sector median.

Each bar is one day's price change; the outlined bar is October 9, 2026. A typical daily move over the past year was 2.3%, so the latest move equals 0.2 times that. Moves outside the dashed lines (about 4.6%) are unusual.

The technical picture

Technically, Halozyme traded very close to its shorter-term averages: it was 0.2% below its 20-day moving average and 4.5% above its 50-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend. The stock has spent 77 consecutive trading days above the 200-day average. The relative strength index was 54, in a neutral range between 30 and 70, and the share price sat 5.5% below the 52-week high.

Closing price over the past year. HALO ends the period 4.2% below its 52-week high, above its 50-day average ($105.65) and above its 200-day average ($79.42).

Momentum has been a defining feature over multi-month horizons. The stock rose 3.2% over one month, 45.1% over three months and 69.4% over one year. The one-year gain was 53.7 percentage points ahead of the S&P 500. Volatility was elevated: it was 45% annualized over 60 days, a reading higher than 81% of its own readings over five years. Together, the trend and momentum scores explain why the stock has run ahead of peers even as daily moves remain muted.

Fundamentals and valuation

On a trailing four-quarter basis through June 30, 2026, Halozyme reported revenue of $1.66 billion, which grew 41.2% from a year earlier. Diluted earnings per share were $3.35, and EPS fell 23.3% from a year earlier. Gross margin was 78.2% versus 81.2% a year earlier, and operating margin was 56.8% versus 57.9% a year earlier. Free-cash-flow margin stood at 48.5% and return on invested capital at 27.4%.

Quarterly revenue by period end. The latest quarter brought $481M, 47.7% more than the same quarter a year earlier.

The balance sheet shows net debt of 2.8 times EBITDA, and share count over one year decreased by 2.4%. Those measures, combined with a high free-cash-flow margin, support the company’s strong PromtFinance scores for Quality 98 (Exceptional) and Stability 83 (Strong), even as profitability metrics showed modest year-on-year erosion.

Valuation metrics show the stock carries a premium to its own recent history. Price to trailing earnings is 33.0 times trailing earnings. That level is higher than 95% of its own readings over the past five years, with a five-year median of 17.1 times earnings. Price to forward earnings is 13.1 times expected earnings and free-cash-flow yield is 6.2%.

PromtFinance places the company high on Growth 82 (Strong) and Momentum 91 (Exceptional), while Revisions 10 (Very weak) signals limited upward estimate revisions.

Earnings and analyst expectations

Halozyme was scheduled to report next on November 2, 2026. The last report, on August 6, 2026, showed earnings per share of $2.28 against $1.79 expected, 27.4% above estimates, and represented the second consecutive quarter beating estimates. Over the last four reports the average surprise was 18.8% below estimates, a pattern that contrasts with the recent beats and suggests more variability in results versus consensus.

Diluted earnings per share by quarter. The latest quarter shows $1.90, against $1.33 in the same quarter a year earlier.

Typical two-day reactions after recent reports have been modest; the typical two-day reaction after recent reports was that the stock rose 1.0%. Analysts covering the stock numbered 27, with 67% assigning Buy-range ratings and a consensus rating of Buy. The consensus price target was $103.00, which was 6.7% below the closing price on October 9, 2026, underlining that the market had priced a premium for the company’s recent performance.

What to watch

November 2, 2026: next scheduled earnings report
August 6, 2026: last reported EPS of $2.28 against $1.79 expected, 27.4% above estimates
October 6 and October 8, 2026: CEO Helen Torley sold a total of 40,000 shares for proceeds of $2,191,600.00 and $2,188,000.00 respectively
Price to trailing earnings of 33.0 times trailing earnings and price to forward earnings of 13.1 times expected earnings
Stock has been above its 200-day average for 77 consecutive trading days

Full HALO analysis: scores, chart and financials →